MetaCap

Apollomics (APLM) vs Werewolf Therapeutics (HOWL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Werewolf Therapeutics (HOWL) has outperformed Apollomics (APLM) over the past year, gaining 8.4% versus a gain of 7.4%. Over five years, HOWL leads with a -93.7% price change compared with -98.4% for APLM. Werewolf Therapeutics is the larger company by market cap ($46.0 million vs $45.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

APLM+7.43%HOWL+8.43%
+102%+14%-73%
Nov 21, 20251 yearNov 20, 2026
APLM-98.43%HOWL-93.68%
+157%+22%-112%
Nov 22, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

APLM versus HOWL key metrics
MetricAPLMHOWL
Share price$15.54$0.9466
Market cap$45.28M$46.00M
1-day change-6.92%-3.97%
YTD return-16.90%+49.31%
1-year return+7.43%+8.43%
5-year return-98.43%-93.68%
EPS (TTM)$-0.25$-0.58
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Net income (latest FY)$-53.86M$-60.82M
52-week high$28.29$1.20
52-week low$12.58$0.27
Distance from 52-week high-45.09%-21.12%
Analyst consensus—none
Avg. price target upside—+639.49%
Average volume11.07K1.08M
Shares outstanding2.91M48.60M
Employees1439
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Apollomics

APLM stock →

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

About Werewolf Therapeutics

HOWL stock →

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.

Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees

APLM vs HOWL FAQ

Which is bigger, Apollomics or Werewolf Therapeutics?

Werewolf Therapeutics (HOWL) is larger, with a market capitalization of $46.00M compared with $45.28M for Apollomics (APLM).

Which stock has performed better over the past year, APLM or HOWL?

HOWL returned +8.43% over the past 12 months, compared with +7.43% for APLM (price return, excluding dividends). Past performance does not predict future results.

Are Apollomics and Werewolf Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons